Solifenacin succinate | YM-67905 | muscarinic receptor antagonist | CAS#242478-38-2

Solifenacin succinate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522451

CAS#: 242478-38-2 (succinate)

Description: Solifenacin succinate is a competitive muscarinic receptor antagoinst used in treatment for an overactive bladder and reduces micturition, urgency, and incontinence. Solifenacin potently blocks signaling through M1, M2, and M3. Solifenacin prevents activation by acetylcholine, resulting in muscle relaxation.

Chemical Structure

Solifenacin succinate

CAS# 242478-38-2 (succinate)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 522451
Name: Solifenacin succinate
CAS#: 242478-38-2 (succinate)
Chemical Formula: C27H32N2O6
Exact Mass: 0.00
Molecular Weight: 480.560
Elemental Analysis: C, 67.48; H, 6.71; N, 5.83; O, 19.98

Price and Availability

Size	Price	Availability
1g	USD 300	2 weeks
5g	USD 650	2 weeks
10g	USD 950	2 weeks
25g	USD 1850	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: YM 905; YM-905; YM905; Solifenacin succinate; brand name: Vesikur; Vesicare.

IUPAC/Chemical Name: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid

InChi Key: RXZMMZZRUPYENV-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)

SMILES Code: C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5.C(CC(=O)O)C(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, DMF, ethanol, and water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#242478-38-2 (Solifenacin succinate); CAS#242478-37-1 (Solifenacin free base).

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Solifenacin is a competitive antagonist of M1, M2, and M3 muscarinic acetylcholine receptors (Kis = 25, 125, and 10 nM, respectively, for the human receptors).
In vitro activity:	To be determined
In vivo activity:	Solifenacin may be a potential therapeutic option for central nervous system demyelinating diseases. Solifenacin treatment significantly promoted myelin regeneration and oligodendrocyte precursor cells differentiation in a cuprizone-induced demyelination mouse model. Solifenacin treatment also inhibited the Wnt/β-catenin signaling pathway and reversed the effects of cuprizone on oligodendrocyte precursor cells differentiation. Reference: J Chem Neuroanat. 2023 Dec 18;136:102375. https://pubmed.ncbi.nlm.nih.gov/38123002/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	25.0	52.02
	DMSO	25.0	52.02
	Ethanol	5.0	10.40
	Water	100.0	208.09

Preparing Stock Solutions

The following data is based on the product molecular weight 480.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Xu X, Song X, Chen F, Yan W, Meng Q, Liu J, Yao R, Liu Y, Dong F. Solifenacin promotes remyelination in cuprizone mouse model by inhibiting the Wnt/β-catenin signaling pathway. J Chem Neuroanat. 2023 Dec 18;136:102375. doi: 10.1016/j.jchemneu.2023.102375. Epub ahead of print. PMID: 38123002. 2. Imamura T, Ogawa T, Minagawa T, Nagai T, Suzuki T, Saito T, Yokoyama H, Nakazawa M, Ishizuka O. Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033. doi: 10.1002/nau.23061. Epub 2016 Jul 1. PMID: 27367573.
In vitro protocol:	To be determined
In vivo protocol:	1. Xu X, Song X, Chen F, Yan W, Meng Q, Liu J, Yao R, Liu Y, Dong F. Solifenacin promotes remyelination in cuprizone mouse model by inhibiting the Wnt/β-catenin signaling pathway. J Chem Neuroanat. 2023 Dec 18;136:102375. doi: 10.1016/j.jchemneu.2023.102375. Epub ahead of print. PMID: 38123002. 2. Imamura T, Ogawa T, Minagawa T, Nagai T, Suzuki T, Saito T, Yokoyama H, Nakazawa M, Ishizuka O. Combined treatment with a β3 -adrenergic receptor agonist and a muscarinic receptor antagonist inhibits detrusor overactivity induced by cold stress in spontaneously hypertensive rats. Neurourol Urodyn. 2017 Apr;36(4):1026-1033. doi: 10.1002/nau.23061. Epub 2016 Jul 1. PMID: 27367573.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6. PubMed PMID: 25814050.

2: Shim M, Kim J, Park S, Choi SK, Lee SM, Huh KO, Song C, Choo MS, Ahn H. The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology. 2015 May;85(5):1123-9. doi: 10.1016/j.urology.2015.01.022. Epub 2015 Mar 4. PubMed PMID: 25746580.

3: Han JY, Lee KS, Park WH, Park CH, Lee JG, Lee JZ, Kim DY, Na YG, Kwon DD, Choo MS. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency. PLoS One. 2014 Nov 17;9(11):e112063. doi: 10.1371/journal.pone.0112063. eCollection 2014. PubMed PMID: 25401784; PubMed Central PMCID: PMC4234319.

4: Bianco FJ, Albala DM, Belkoff LH, Miles BJ, Peabody JO, He W, Bradt JS, Haas GP, Ahlering TE. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. J Urol. 2015 Apr;193(4):1305-10. doi: 10.1016/j.juro.2014.09.106. Epub 2014 Oct 2. PubMed PMID: 25281778.

5: Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014 Nov;25(11):1479-82. doi: 10.1007/s00192-014-2396-8. Epub 2014 May 7. PubMed PMID: 24803216.

6: Huo LZ, Jing HG, Wang TC, Yuan SX, Luan XH, Guo KC, Shi BK. [A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder]. Zhonghua Yi Xue Za Zhi. 2013 Nov 26;93(44):3526-8. Chinese. PubMed PMID: 24521895.

7: Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest. 2013;75(4):230-4. doi: 10.1159/000350216. Epub 2013 Mar 28. PubMed PMID: 23548260.

8: Singh L, Nanda S. Spectrophotometric estimation of solifenacin succinate in tablet formulations. Pharm Methods. 2011 Jan;2(1):21-4. doi: 10.4103/2229-4708.81086. PubMed PMID: 23781425; PubMed Central PMCID: PMC3658025.

9: Krishna SR, Rao BM, Rao NS. A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. J Chromatogr Sci. 2010 Nov;48(10):807-10. PubMed PMID: 21044410.

10: Ohtake A, Sato S, Sasamata M, Miyata K. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4. Review. PubMed PMID: 20134114.

Your view history

Solifenacin succinate featured